S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

APTO Aptose Biosciences Inc

0.2851

0.012 (4.39%)

Pre Market

Last Updated: 23:10:57

Delayed by 15 minutes

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

null

Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Aptose Biosciences Charts.

Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Aptose Biosciences Charts.

Aptose Biosciences Inc News

Form 8-K - Current report
Thursday 21 November 2024 (1 day ago) • Edgar (US Regulatory)

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Wednesday 20 November 2024 (1 day ago) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Friday 15 November 2024 (7 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Saturday 9 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Aptose Reports Results for the Third Quarter 2024
Saturday 9 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Thursday 31 October 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Saturday 5 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Saturday 7 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 6 September 2024 (3 months ago) • Edgar (US Regulatory)

Aptose Announces Results from Special Meeting of Shareholders
Friday 6 September 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Saturday 31 August 2024 (3 months ago) • Edgar (US Regulatory)

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Saturday 31 August 2024 (3 months ago) • GlobeNewswire Inc.

More Aptose Biosciences Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions